Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules

This post was originally published and is credit to this site

MONMOUTH JUNCTION, N.J., June 23, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 8,407,411 shares of its common stock, at a purchase price of $1.215 per share, for aggregate gross proceeds of approximately $10.2 million.

H.C. Wainwright & Co. is acting as the exclusive placement agent.